Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: Analysis of 1,446 patients from the pancreatic cancer cohort in a single institution

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Park, Joo Kyung ^a   Paik, Woo Hyun ^a   Ryu, Ji Kon ^a   Kim, Yong Tae ^a   Kim, Youn Joo ^a   Kim, Jaihwan ^a   Song, Byeong Jun ^a   Park, Jin Myung ^a   Yoon, Yong Bum ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; TUMOR MARKER;

AGED; ARTICLE; BLOOD LEVEL; CA 19-9 BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE MARKER; FEMALE; HISTOPATHOLOGY; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; POSTOPERATIVE PERIOD; STATISTICAL ANALYSIS; ADENOCARCINOMA; ADULT; BLOOD; CARCINOMA, PANCREATIC DUCTAL; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROGNOSIS; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CARCINOMA, PANCREATIC DUCTAL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84892622763     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078977     Document Type: Article

References (38)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Conlon KC, Klimstra DS, Brennan MF (1996) Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 223: 273-279.
3. Mancuso A, Calabro F, Sternberg CN (2006) Current therapies and advances in the treatment of pancreatic cancer. Crit Rev Oncol Hematol 58: 231-241.
4. Hata S, Sakamoto Y, Yamamoto Y, Nara S, Esaki M, et al. (2012) Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol 19: 636-641.
5. Ballehaninna UK, Chamberlain RS (2012) The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol 3: 105-119.
6. Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, et al. (2007) Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 8: 773-783.
7. Park JK, Ryu JK, Yoon WJ, Lee SH, Lee GY, et al. (2012) The role of quantitative NPTX2 hypermethylation as a novel serum diagnostic marker in pancreatic cancer. Pancreas 41: 95-101.
8. Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, et al. (2006) New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol 24: 252-258.
9. Argani P, Rosty C, Reiter RE, Wilentz RE, Murugesan SR, et al. (2001) Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res 61: 4320-4324.
10. Harsha HC, Kandasamy K, Ranganathan P, Rani S, Ramabadran S, et al. (2009) A compendium of potential biomarkers of pancreatic cancer. PLoS Med 6: e1000046.
11. Suwa H, Ohshio G, Okada N, Wang Z, Fukumoto M, et al. (1997) Clinical significance of serum p53 antigen in patients with pancreatic carcinomas. Gut 40: 647-653.
12. Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V (2006) Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 70: 255-264.
13. Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, et al. (2008) CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 9: 132-138.
14. Bhat K, Wang F, Ma Q, Li Q, Mallik S, et al. (2012) Advances in biomarker research for pancreatic cancer. Curr Pharm Des 18: 2439-2451.
15. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, et al. (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24: 5313-5327.
16. Glenn J, Steinberg WM, Kurtzman SH, Steinberg SM, Sindelar WF (1988) Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 6: 462-468.
17. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, et al. (1987) Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 47: 5501-5503.
18. Schlieman MG, Ho HS, Bold RJ (2003) Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 138: 951-955; discussion 955-956.
19. Berger AC, Garcia M, Jr., Hoffman JP, Regine WF, Abrams RA, et al. (2008) Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 26: 5918-5922.
20. Maithel SK, Maloney S, Winston C, Gonen M, D'Angelica MI, et al. (2008) Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol 15: 3512-3520.
21. Halm U, Schumann T, Schiefke I, Witzigmann H, Mossner J, et al. (2000) Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 82: 1013-1016.
22. Ziske C, Schlie C, Gorschluter M, Glasmacher A, Mey U, et al. (2003) Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 89: 1413-1417.
23. Reni M, Cereda S, Balzano G, Passoni P, Rognone A, et al. (2009) Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 115: 2630-2639.
24. Magnani JL, Nilsson B, Brockhaus M, Zopf D, Steplewski Z, et al. (1982) A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem 257: 14365-14369.
25. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247.
26. Deugnier YM, Rabot AF, Guyader D, Moirand R, Turlin B, et al. (1994) Serum increase and liver overexpression of carbohydrate 19.9 antigen in patients with genetic haemochromatosis. Gut 35: 1107-1111.
27. Pearce S, Thornes H, Carr D, Tanner A (1994) Diagnostic pitfall; interpretation of CA 19-9 concentrations in the presence of hepatic dysfunction. Gut 35: 707-708.
28. Pleskow DK, Berger HJ, Gyves J, Allen E, McLean A, et al. (1989) Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 110: 704-709.
29. Schmiegel WH, Kreiker C, Eberl W, Arndt R, Classen M, et al. (1985) Monoclonal antibody defines CA 19-9 in pancreatic juices and sera. Gut 26: 456-460.
30. Hori SS, Gambhir SS (2011) Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations. Sci Transl Med 3: 109ra116.
31. Boeck S, Haas M, Laubender RP, Kullmann F, Klose C, et al. (2010) Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer. Clin Cancer Res 16: 986-994.
32. Gold DV, Goggins M, Modrak DE, Newsome G, Liu M, et al. (2010) Detection of early-stage pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 19: 2786-2794.
33. Haglund C, Roberts PJ, Kuusela P, Scheinin TM, Makela O, et al. (1986) Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer 53: 197-202.
34. Yue T, Maupin KA, Fallon B, Li L, Partyka K, et al. (2011) Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers. PLoS One 6: e29180.
35. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, et al. (2005) Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer 93: 195-199.
36. Wasan HS, Springett GM, Chodkiewicz C, Wong R, Maurel J, et al. (2009) CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone. Br J Cancer 101: 1162-1167.
37. Maisey NR, Norman AR, Hill A, Massey A, Oates J, et al. (2005) CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer 93: 740-743.
38. Barton JG, Bois JP, Sarr MG, Wood CM, Qin R, et al. (2009) Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma. J Gastrointest Surg 13: 2050-2058.